Pharmacological and molecular mechanisms behind the sterilizing activity of pyrazinamide
Inclusion of pyrazinamide (PZA) in the tuberculosis (TB) drug regimen during the 1970s
enabled a reduction in treatment duration from 12 to 6 months. PZA has this remarkable …
enabled a reduction in treatment duration from 12 to 6 months. PZA has this remarkable …
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised …
F von Groote-Bidlingmaier, R Patientia… - The Lancet …, 2019 - thelancet.com
Background Delamanid is one of two recently approved drugs for the treatment of multidrug-
resistant tuberculosis. We aimed to evaluate the safety and efficacy of delamanid in the first …
resistant tuberculosis. We aimed to evaluate the safety and efficacy of delamanid in the first …
Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update
The global control and management of tuberculosis (TB) is faced with the formidable
challenge of worsening scenarios of drug-resistant disease. Pyrazinamide (PZA) is an …
challenge of worsening scenarios of drug-resistant disease. Pyrazinamide (PZA) is an …
Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA …
J Werngren, E Sturegård, P Juréen… - Antimicrobial Agents …, 2012 - Am Soc Microbiol
Pyrazinamide (PZA) is a potent first-line agent for the treatment of tuberculosis (TB) with
activity also against a significant part of drug-resistant Mycobacterium tuberculosis strains …
activity also against a significant part of drug-resistant Mycobacterium tuberculosis strains …